FRESENIUS KABI

caring for life

Diben

For better glycaemic control

1 kcal/mL tube feed with fibre and with fish oil for the dietary management of patients with or at risk of malnutrition with impaired glucose metabolism such as in impaired glucose tolerance, stress-induced hyperglycaemia, diabetes mellitus

With clinical evidence from multicentre trial demonstrating improved long-term glycaemic control, minimized blood glucose fluctuations and reduced insulin requirements[1,2]

- Modified carbohydrate profile with low glycaemic index for improved glycaemic control[3,4]
- Balanced fat profile: high in monounsaturated fatty acids (MUFA) to improve glycaemic control[5-7] and insulin sensitivity[8-10], with fish oil for cardiovascular protection[11-13]
- Increased chromium to improve insulin sensitivity[14]

For Health Care Professionals only.

Diben

Ready to use in 500 mL EasyBag

Nutritional Information

Average content		Diben 100mL
Energy value	kJ (kcal)	440 (105)
Fat (43% Energy)	g	5.0
of which saturated fatty acids	g	0.46
of which monounsaturated fatty acids	g	3.67
of which polyunsaturated fatty acids	g	0.87
of which EPA* + DHA**	g	0.17
of which cholesterol	mg	≤ 5.0
Carbohydrate (35% Energy)	g	9.25
of which starch	g	6.50
of which sugars	g	2.41
of which fructose	g	2.20
of which lactose	g	≤ 0.1
Glycaemic Index		29
Fibre (5% Energy)	g	2.4
Protein (17% Energy)	g	4.5
Salt	g	0.21
Water	mL	83.0
Lactose Content	g	≤ 0.1
Gluten Content	ppm	≤ 5
Osmolarity	mosmol/l	270
Osmolality	mosmol/kg H_2O	330
Minerals and trace elements		
Sodium	mg/mmol	85/3.7
Potassium	mg/mmol	143/3.7
Chloride	mg/mmol	124/3.5
Calcium	mg/mmol	88/2.2
Magnesium	mg/mmol	31/1.3
Phosphorus	mg	59
Iron	mg	1.48
Zinc	mg	1.33
Copper	µg	148
Manganese	mg	0.30
Iodine	µg	14.8
Fluoride	mg	0.15
Chromium	µg	29.6
Molybdenum	µg	11.1
Selenium	µg	7.4
Vitamins and other nutrients†		
Vitamin A	µg RE°	200
of which β-Carotene	µg RE°	122
Vitamin D_3	µg	1.1
Vitamin E	mg α-TE°°	7.4
Vitamin K_1	µg	7.4
Thiamine (Vitamin $B_{1)}$	mg	0.15
Riboflavin (Vitamin $B_{2)}$	mg	0.19
Niacin	mg/mg NE°°°	1.8/3.0
Vitamin B_6	mg	0.18
Vitamin B_{12}	µg	0.30
Pantothenic acid	mg	0.52
Biotin	µg	5.6
Folic acid	µg	29.6
Vitamin C	mg	18.5
Choline†	mg	40.7

*eicosapentaenoic acid **docosahexaenoic acid
° RE: retinol equivalents; °°α-TE: alpha-tocopherol equivalents;
°°°NE: niacin equivalents

Prescribing information

Food for special medical purposes:
Nutritionally complete tube feed (1.05 kcal/mL) with fibre. High in monounsaturated fatty acids, with EPA* and DHA** from fish oil. Increased in β-carotene, vitamin E and magnesium; with green tea extract; modified carbohydrate profile with low glycaemic index and increased glucose tolerance cofactor chromium for improved glycaemic control. Low in lactose and gluten, low in sodium, low in cholesterol. For the dietary management of patients with or at risk of malnutrition in particular for patients with impaired glucose metabolism.

Dosage:
Must be determined by the health care professional according to patients' needs. Recommendation for complete nutrition ≥ 1350 mL (1415 kcal)/day or supplementary nutrition ≥ 500 mL (525 kcal)/day.

Important notes:
To be used under medical supervision. Monitor feeding rate. Suitable as sole source of nutrition. Not suitable for children < 3 years. Use with caution in children < 6 years. Contains caffeine (3.3 mg/100 mL). Not suitable for patients with galactosaemia. Ensure adequate fluid intake. Drug therapy for blood sugar control should be adjusted accordingly. **Not for parenteral (I.V.) use!**

Instruction for use:
Store at room temperature. Once opened, use within 24 hours. Shake well before use! Do not use if bag is damaged or swollen or content is coagulated. Do not mix with drugs.

Contraindications:
Not suitable whenever enteral nutrition is not permitted such as in acute gastrointestinal bleeding, ileus and shock. Use with caution in severe organ failure with impaired metabolism and severe forms of malassimilation. Not suitable for patients with congenital inability to metabolise nutrients contained in Diben.

Ingredients

Water, modified starch, milk protein, vegetable oils (sunflower oil, safflower oil), fructose, fish oil, maltodextrin, emulsifiers (E 471, soya lecithin), cellulose, potassium chloride, natural flavouring, acidity regulators (E 170, E 524), stabilisers (E 452, E 460, E 466), potassium citrate, choline hydrogen tartrate, vit. C, magnesium oxide, green tea extract (0.04 %), sodium chloride, vit. E, iron pyrophosphate, zinc sulphate, niacin, β-carotene, manganese chloride, pantothenic acid, vit. B1, copper sulphate, sodium fluoride, vit. B2, vit. B6, vit. A, chromium chloride, folic acid, sodium molybdate, sodium selenite, potassium iodide, vit. K1, biotin, vit. D3, vit. B12.
Allergen Information: This product contains milk, soy and fish oil.

References

1) Pohl M et al. Glycaemic control in type II diabetic tube-fed patients with a new enteral formula low in carbohydrates and high in monounsaturated fatty acids: a randomised controlled trial. Eur J Clin Nutr. 2005;59(11):1221-1232.
2) Pohl M et al. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial. JPEN. 2009;33(1):37-49.
3) Thomas DE & Elliott EJ. The use of low-glycaemic index diets in diabetes control. Br J Nutr. 2010;104(6):797-802.
4) Barazzoni R et al. Carbohydrates and insulin resistance in clinical nutrition: Recommendations from the ESPEN expert group. Clin. Nutr. 2017;36(2): 355-363. 5) Pohl M et al. Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula: stage II of a randomized, controlled multicenter trial. JPEN. 2009;33(1):37-49.
6) Lochs H et al. Introductory to the ESPEN Guidelines on Enteral nutrition: terminology, definitions and general topics. Clin Nutr. 2006;25(2):180-186.
7) Qian F et al. Metabolic effects of monounsaturated fatty acid-enriched diets compared with carbohydrate or polyunsaturated fatty acid-enriched diets in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):1448-1457.
8) Paniagua JA et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care. 2007;30(7):1717-1723.
9) Brehm BJ et al. One-year comparison of a high-monounsaturated fat diet with a high carbohydrate diet in type 2 diabetes. Diabetes Care. 2009;32(2):215-220.
10) Gadgil MD et al. The Effects of Carbohydrate, Unsaturated Fat, and Protein Intake on Measures of Insulin Sensitivity. Diabetes Care. 2013;36(5):1132-1137. 11) Kris-Etherton PM et al. Dietary reference intakes for DHA and EPA. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2009;81(2-3):99-104.
12) International Society for the Study of Fatty Acids and Lipids (ISSFAL): Recommendations for Dietary Intake of Polyunsaturated Fatty Acids in Healthy Adults. Report June 2004.
13) Lee JH et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332
14) Suksomboon N et al. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J. Clin Pharm Ther 2014;39(3):292-306.

FRESENIUS KABI
caring for life

Fresenius Kabi Australia Pty Limited
Level 2, 2 Woodland Way,
Mount Kuring-gai NSW 2080
Phone 1300 732 001
Fax 1300 304 384
www.fresenius-kabi.com.au

Fresenius Kabi New Zealand Limited
60 Pavilion Drive, Māngere
Auckland 2022 New Zealand
Phone 0800 144 892
Fax +64 9925 2721

PM2017.321V5 Pub: October 2019